Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (945)	11/24/1997 2:16:00 PM
From: Steve Harmon	Respond to of 2742

Richard, Good points on IL-l value. Minimum value of IL-1 is $21 mil. plus the cash hoard of $15 million. Cistron's minimum value is $36 million. Current market value is $6.4 million. Kind of a humorous situation.

To: scaram(o)uche who wrote (945)	11/25/1997 12:10:00 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 2742

Galton/BlueStone: Galton..... you don't get out often enough. You have let a year pass, with one of biotech's most secure patent positions, having done NOTHING other than protect CIST cash. I never, in my wildest dreams, imagined that you would let a year pass and then, admitting your own incompetence, hire in BlueStone. Do you understand the significance of the Levy manuscript? Have you tried to reproduce the results? Do you sit around your office pounding the side of your head saying "duh"? Do you understand that you have several RATIONAL projects in hand that are sealed tightly within the realm of your patents? Do you derive your sum knowledge of immunology from IMNX press releases? Do you entirely lack immagination, perspective on modern biotech business plans, and/or an understanding of biology? Shareholders..... let's start to organize for the annual meeting. We need to expose and highlight Galton's incompetence. Does anyone have a route to Grausz? I may elect to contact Warner-Lambert and Dr. Edelman. Galton..... here's another company to contact regarding potential synergies...... StressGen Biotechnologies Corporation FOR IMMEDIATE RELEASE November 25, 1997 Preclinical study confirms StressGen's technology offers new approach in the fight against infection and cancer . Whitehead scientists show stress protein fusions work through MHC class I pathway to activate killer T cells . Findings published in the Journal Proceedings of the National Academy of Sciences VICTORIA, British Columbia StressGen Biotechnologies Corp. (TSE/VSE: SSB) today announced preclinical experiments performed at the Whitehead Institute of Biomedical Research in Cambridge, Mass., confirm that the Company's proprietary technology effectively activates the killer cells or CTLs necessary to destroy cancer and virus-infected cells. This ability to activate CTLs overcomes a long-standing problem in vaccine development and offers a new approach to the treatment of cancer and infectious diseases. Results from the study, led by Dr. Richard Young of the Whitehead Institute of Biomedical Research, an affiliate of the Massachusetts Institute of Technology (MIT), were published today in the Journal Proceedings of the National Academy of Sciences. Dr. Young is the co-inventor of StressGen's core technology and has been a pioneer in investigating the broad applications of stress proteins. He is a member of StressGen's Board of Directors and also sits on the Company's Scientific Advisory Board. In 1992 StressGen obtained a worldwide exclusive license from the Whitehead institute to make, use and sell products based upon certain discoveries related to stress proteins made by researchers at MIT. In the study, scientists created a recombinant protein by fusing together a stress protein from M. tuberculosis and a protein called ovalbumin, long used by immunologists to study immune function. When the recombinant fusion protein was injected into mice the animals mounted an immune response against ovalbumin and developed immunity against cancer cells that make ovalbumin. The scientists showed that these soluble fusion proteins can function as vehicles to deliver viral proteins to the immune system pathway responsible for stimulating a CTL response -- the major histocompatibility complex (MHC) class I presentation pathway. "We are encouraged by these results as they provide additional scientific validation of the stress protein fusion vaccine approach," said Richard M. Glickman, StressGen's President and Chief Executive Officer. MORE . . . When infection enters the body the immune system responds in two ways. One arm of the immune system, led by immune cells called B cells, works by secreting antibodies into the body's bloodstream. These antibodies seek and destroy the infectious agents circulating in the bloodstream. However, antibodies have little effect on infected cells. The task of attacking cells infected by viruses or deformed by cancer falls to a second arm of the immune system, led by immune cells called T cells. T cells orchestrate a multi-pronged attack and, if appropriate, produce killer cells called cytotoxic T cells or CTLs that home in on infected cells and destroy them. For decades vaccine development experts have sought a simple and practical way to produce an immune response that activates both arms of the immune system using soluble proteins. However, vaccines containing soluble proteins from microorganisms rarely activated a response that included CTLs. "We were able to solve this problem by taking advantage of the observation that a class of proteins, called heat-shock proteins or stress proteins, are exceptions to the rule that soluble proteins are unable to stimulate CTL responses. In fact, heat shock proteins are extremely potent in stimulating a CTL immune response," said Dr. Young. StressGen's intellectual property position includes granted patents covering the use of stress proteins and their fragments as vaccines for infectious disease and cancer. In addition, further patent applications cover novel stress protein genes and novel fusions of stress proteins and various protein antigens. StressGen Biotechnologies Corporation is a biopharmaceutical company engaged in the research and development of stress proteins for use in cancer treatments and vaccines to prevent infectious disease. The Company is also an international leader in the development, manufacture and sale of stress protein research biochemicals. ### The title of the PNAS paper is "Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class 1 presentation pathway." The authors are: Kimiko Suzue, Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology. Xianzheng Zhou, Department of Biology and Center for Cancer Research, Massachusetts Institute of Technology. Herman N. Eisen, Department of Biology and Center for Cancer Research, Massachusetts Institute of Technology. Richard Young, Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology. -30- For more information contact: Michelle Lurch-Shaw StressGen Biotechnologies (250) 744-2811 ----------------------------------- Michelle Lurch-Shaw Manager of Communications StressGen Biotechnologies Corp. Tel: 250-744-2811 Fax:250-744-2877 website: www.stressgen.com